Ozempic and Wegovy maker Novo Nordisk quieted Wall Street’s concerns with its fourth-quarter results and 2025 outlook.

Novo Nordisk (NVO) stock in focus as company announces new Phase 3 trial for its next-gen weight loss drug CagriSema despite ...

CagriSema, which underperformed expectations in its first Phase 3 test, will be studied at different doses and for longer ...

Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's ...

The Tigers will have a week to lick their wounds from this loss before they are back on the road for their sixth SEC matchup of the season. They will face another ranked foe in No. 4 Alabama at 7: ...

She’s racing to a run-through for a 14-course tasting menu she will barely nibble at as she raves about her weight loss on ...

Against a fellow winless team in the SEC, Arkansas (11-6, 0-4) let leads of 12 and eight points slip away in a 78-74 loss at LSU (12-5, 1-3). After three losses to three ranked teams to kick off the ...

So far, Retatrutide, developed by Eli Lilly, has achieved an efficacy rate of 24%, ahead of CagriSema. Previously, the biggest challenge facing Novo Nordisk and Eli Lilly — beyond their rivalry — was ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight loss versus the ... I have no business relationship with any company ...

Georgia basketball hung with No. 6 Tennessee through 20 minutes before falling apart at a hostile Thompson-Boling Arena Wednesday night. The No. 23-ranked Bulldogs (14-3, 2-2 SEC) held a 26-25 ...